Member Info for JohnnyB1

i just thought i would google images of the potomac ballroom.

https://thevendry.com/venue/164140/***lord-national-resort-convention-center-oxon-hill-md/space/34600

it is massive and certainly should be a step up from scrumming around a poster for 3 hours.

nermeen varawalla stands up to speak at 2.30 pm et (that is 7.30 pm uk time).

Miavoce. Thank you for pointing that out, I see it does show as 2.30 pm Saturday Nov 8. Confusingly it also shows on Friday Nov 7 as stated as stated in the link on my post and in Cleaner's post.

According to this link (kindly provided by Cleaner in an earlier post) the presentation is tomorrow 7 November but I do not know the time:-

https://www.sitcancer.org/2025/abstracts/titles-and-publications?SITC%202025%20Abstracts%5BrefinementList%5D%5BPresentation%20Type%5D%5B0%5D=Oral&SITC%202025%20Abstracts%5BrefinementList%5D%5BAbstract%20Type%5D%5B0%5D=Late-Breaking%20Abstract

The link also states:-

" Oral Presentation Data Embargo"

"Any updated and/or new data that will be available in an oral presentation is embargoed until the date and time of the presentation. If the oral presenter is also creating a poster which includes updated and/or new data, the poster shares the same Oral Presentation Embargo date, not the poster embargo date specified above. This embargo applies to oral abstract presentations."

I may be wrong but I my interpretation is that it will include new data and that we will get a RNS contemporaneously with the start of the presentation. The following link states:-

"Late-Breaking Abstract - Clinical Only (LBA) Information and Eligibility"

"Late-breaking Abstract (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late.” The LBA deadline is not intended to be an extension of the general submission deadline. LBAs highlight novel and practice-changing in-human clinical studies and only apply to data that would have not otherwise have been presented as an abstract at the 40th Anniversary Annual Meeting."

To me the wording "................ data that would have not otherwise have been presented as an abstract at the 40th Anniversary Annual Meeting" implies to me that it is new data:-

https://www.sitcancer.org/2025/abstracts/abstract-submission/abstract-lba

Interesting. I guess it helps explain why the share price hasn't yet succumbed to gravity since the recent Diggle buy. Let's hope the buys continue.

CONTINUED FROM PREVIOUS POST:

"Proficiency in Microsoft Office, CRM systems, and digital engagement tools such as Veeva Engage.

Fluency in English, with outstanding organizational, communication, and presentation skills.

Willingness to travel across the UK as required.

Preferred Qualifications

Experience and demonstrable success in launching new products within the oncology space in the UK market.

Strong knowledge of NHS and private sector oncology reimbursement frameworks.

About You

You are genuinely passionate about our purpose

You bring precision and excellence to all that you do

You believe in our rooted-in-science approach to problem-solving

You are a generous collaborator who can work in teams with a broad spectrum of backgrounds

You take pride in enabling the best work of others on the team

You can grapple with the unknown and be innovative

You have experience working in a fast-growing, dynamic company (or a strong desire to)

You work hard and are not afraid to have a little fun while you do so!

Locations

Genmab maximizes the efficiency of an agile working environment, when possible, for the betterment of employee work-life balance. Our offices are crafted as open, community-based spaces that work to connect employees while being immersed in our powerful laboratories. Whether you’re in one of our office spaces or working remotely, we thrive on connecting with each other to innovate."

I don't know whether this is Scancell related but I thought I would post it anyway for information. Perhaps linked to the Cancer Vaccine Launchpad?

If you go on LinkedIn and search for "Genmab Inc" you will see that they have advertised for two positions. The second advert caught my attention:-

"National Account Lead, UK Genmab · London, England, United Kingdom

The Role"

"The National Account Lead will play a pivotal role in establishing Genmab in the UK, with accountability for translating the UK strategy into operational launch readiness in the NHS and private sectors with a focus on the coordination, development and management of working with the highest tiers of UK KOLs, specialist cancer centers, private hospitals, private sector stakeholders and key decision makers.

This role will work closely with the UK GM, Medical lead and access teams.

Responsibilities

Based on the Launch Readiness strategy, develop and implement an operational plan that meets or exceeds sales objectives, by appropriately positioning the benefits of Genmab’s products for oncology patients.

Develop and execute national advocacy plan and facilitate product adoption by developing long-term, value-led relationships with national top tier healthcare professionals, care coordination teams and field-based payors.

Demonstrate strong commercial acumen through market analysis, understanding competitor dynamics, and adapting strategies and tactics accordingly.

Manage & develop top tier private sector stakeholders – HCP, Insurance groups and hospitals

Manage resources and budget effectively and in accordance with internal guidelines.

Ensure full compliance with all relevant UK laws, ABPI/industry codes of practice, NHS regulations, and Genmab internal policies.

Engage flexibly through both virtual and face-to-face interactions, tailoring approaches to customer preferences and enhancing access to stakeholders.

Champion Genmab’s oncology portfolio with integrity and professionalism, upholding ethical standards in all external interactions.

Drive excellence in territory management through strategic planning, optimal use of tools and resources, and consistent execution of sales initiatives.

Requirements

Minimum of 8 years’ experience in pharmaceutical sales, with at least 3 years in the oncology space. Expertise in gynaecological oncology and/or antibody-drug conjugates (ADC) is highly desirable.

Proven experience across both large pharmaceutical companies and smaller biotech organizations, with a strong grasp of the UK oncology ecosystem.

A successful track record in meeting or exceeding sales targets in complex therapeutic areas and leading a team.

Demonstrated ability to build and maintain relationships with Key Opinion Leaders (KOLs), multidisciplinary teams, and key accounts in the solid tumor market.

Sound knowledge of the UK oncology reimbursement landscape and pathways, including NHS commissioning structures and funding mechanisms for injectable therapies.

Excellent multitasking ability and attention to detail in a fast-paced environment."

CONTINUED OIN NEXT POST

Genmab appoints Matt Kiely as General Manager for the United Kingdom:-

https://ir.genmab.com/news-releases/news-release-details/genmab-appoints-matt-kiely-general-manager-united-kingdom

"Matt Kiely joins Genmab as the company strengthens its commercialization capabilities in Europe and prepares to bring its innovative antibody-based medicines to more patients"

"As part of the company’s expansion into commercial markets in Europe, Genmab is now establishing its presence in the United Kingdom with the appointment of Matt Kiely as General Manager. In this role, Matt will lead the UK business operations, ensuring the success of future product launches and supporting Genmab’s mission to bring innovative medicines to more patients. He joins Genmab on September 1."

Burble, thank you for explaining that, I appreciate it. AI hadn't even crossed my mind. EE I totally agree it can be misleading.

I was not aware of this:"Scancell - doing incredible work developing cancer vaccines, including those targeting blood cancers."

This is a Linked-in post made 4 hours ago by Meryn Bailey - Business Development Officer - MedTech and Life Sciences:-

"September is Blood Cancer Awareness Month, a time to recognise the incredible work being done to fight blood cancers.

There’s so much innovation happening in MedTech and Life Sciences to improve detection, treatment and patient care. Some of the companies making a real impact include:

🩸Autolus Therapeutics - specialise in T cell therapies for blood cancers.

🩸Alethiomics - focuses on blood cancer treatments, leveraging advanced technologies for therapeutic development.

🩸Adaptimmune - T-cell therapies targeting cancer, including blood cancers.

🩸Scancell - doing incredible work developing cancer vaccines, including those targeting blood cancers.

🩸T-Cypher Bio - focuses on T-cell receptor -based therapeutics for cancer, including blood cancers.

🩸Oxford Cancer Analytics - developing blood tests for early cancer detection, including blood cancers, using proteomics and AI.

It’s inspiring to see how research and tech come together to help patients and their families. Here's to continuing to supporting and celebrating the people and companies making a difference."

Cohesion Bureau’s Post on Linked-in

https://www.linkedin.com/posts/cohesion-bureau_immunotherapy-oncology-cancerresearch-activity-7364322732123037696-dxEo

What is the future of next-generation immunotherapies for cancer?

Join us for a panel discussion on this rapidly advancing field:

📅 Date: Monday, 25 August 2025

⏰ Time: 5:00 PM CET

Scancell and Enterome have reached positive Phase 2 milestones with a new generation of active immunotherapies to treat melanoma and blood cancers, respectively. Their highly differentiated approaches offer insights and strategies for harnessing the immune system more effectively.

Speakers:

· Phil L'Huillier, CEO, Scancell

· Belichard Pierre, CEO, Enterome

Moderator:

· Chris Maggos, Cohesion Bureau

Register now: https://lnkd.in/eEVZT_uR

A big thank you to Patrik Frei for hosting this session as part of the Biotechgate Digital Partnering Conference.

📌 Full program available via the link in the first comment.

#Immunotherapy #Oncology #CancerResearch #Biotech #LifeSciences #ClinicalTrials #DrugDevelopment #Biopharma #CancerTreatment

Yes WTP,

In a similar vein, I was looking at Scancell's last post on Linked-in (6 days ago) about the Scope Trial; this states "These results signal a potential new standard in melanoma treatment and a clear path to late-stage development, which we are accelerating planning for."

I noticed that this post was liked by David Hemmah, Business Development Associate at Fingerpaint Branding. His profile states:-

"At Fingerpaint Branding (formerly Leaderboard Branding), a global brand consultancy with niche expertise in pharmaceutical naming and branding, I work on developing impactful brand strategies that drive success and growth. I'm passionate about helping our clients create brands that stand out and make a difference."

A number of Fingerpaint Branding's posts on Linked-in are congratulating Pharmaceutical Companies, that they are in partnership with, on FDA and EMA approval of their drugs:-

https://www.linkedin.com/company/fingerpaint-branding?trk=public_profile_topcard-current-company

Maybe Scancell will enter into some sort of partnership with Fingerpaint Branding.

RayP.,

"current standard of card", you'll have to be careful you don't start another conversation about cardboard laboratories :-)

I have only just noticed that Diggle total buys 15 May'25 to 7 August'25 total precisely 10 million shares (49,868 + 402,952 + 44,944 + 5,000,000 + 4,400,000 + 102,236 =10,000,000).

There was an interesting comment 4 days ago by the lady on the MM site (She was treated for Renal Cell Carcinoma and was the second patient to be assessed in Cohort 4 - Modi-1 combined with CPI). She says:-

"Yeah, when I joined here, I'd already asked for my prognosis which was 5 years = Dec 2026. Once I got in the swing of it, and we discussed it on here, regularly, I decided a prognosis didnt help. I changed my approach to reading-the-room instead. I never broached the "how long" question again. But when I stopped my treatment last year, my onco shared he thought I'd be good for many more years. 30 in fact. I think he forgot my age (56)! I tried to play it down, because I reallly believe in my approach ie Everyone is different, just "stats", you never know etc.

5,000,000 plus 4,150,000 that's now 0.88% (If its the same person).

Miavoce,

Thank you for explaining that, I had not spotted that it says "Probability" on the left axis. I must admit I was confused by the combined Cohort 1 and Cohort 3 graph on page 22 of the presentation showing PFS at 22 months (given that the graph for Cohort 3 only extends to 11 months) but that explains it.

Just to add that in respect of Cohort 3 (n= 29) on pages 18 and 19.

This states Progression free survival at 11 months = 80.8%. This must be 21 progression free out of 26 patients (This would make sense as not all 29 patients will have been on the trial for 11 months).

I very rarely look at the other channel because of all the in fighting, but there has been a lot of conversation on there about the Scope Trial.

My understanding of the argument is that some are saying the trial results can't be relied on if Scancell have excluded data on patients that had progressive disease within the first 3 months and did not reach the first 13 week scan.

I refer to the presentation slide:-

https://scancell.co.uk/wp-content/uploads/2025/07/Scancell-iSCIB1-strongly-improved-outcomes-in-Late-Stage-Melanoma-SCOPE-study-results.pdf

If you look at Cohort 1 on page 13 you will see that the ORR and DCR are both calculated on data from 38 patients (n = 38). This is contradicted by page 11 which states Cohort 1 (n= 43). Maybe 5 patients had PD before week 13 and were excluded and the argument being put forward is that they should be included to calculate the ORR and DCR.

A further complication that has not been discussed over there arises when we look at Cohort 1 Progression Free Survival on page 14. This again states (n= 38) and Progression Free Survival at 22 months is 64.6%. The complication is that whatever number of patients are progression free, if you divide this by 38 it is not mathematically possible to come up with an answer of 64.6%.

The only way I can reach an answer of 64.6% is if 31 out of 48 patients (yes 10 more than the 38) are progression free (31 divided by 48 = 64.5833 i.e. 64.6% to one decimal place). The important thing here is that this still exceeds the current standard of care. (For completeness the only other answer that comes close would be 20 progression free patients out of 31 = 64.516% but that would be 64.5% to one decimal place).

I also believe it is a good thing that Scancell will be able to use biomarkers to identify suitable patients for the Phase 3 Trial. If the vaccine works on this 80% suitable population it will be fantastic. It is certainly a big step up if you compare this much more expensive personalised MRNA vaccines that are tailor made to just one individual.

Hi Magnet,

Thank you for that, I appreciate it.

Sorry I was unaware that the error was spotted previously. It probably is just a genuine mistake, but it does make me wonder if there could be more to it given BioNTech's link to the Cancer Vaccine Launchpad and the fact that it is a also melanoma study.

This is weird. I just went on Scancell's website and clicked on "News", I then clicked on "Partnership with NHS Cancer Vaccine Launchpad .......... 14 April 2025", this takes you to the following document:-

https://scancell.co.uk/wp-content/uploads/2025/04/250414-Scancell-CVLP_Press-Release_NEW-FINAL.pdf#new_tab

Go towards the bottom of the document to the section headed "About the SCOPE Study".

Here you will find a link to the Scope Study (NCT04079166). Ignore that, as you might expect it takes you to the Scope Study. Instead go to the bottom of the paragraph and click on the blue highlighted "clinical trials.gov", surprisingly this takes you to BioNTech SE's Advanced Melanoma Study.

Clearly someone at Scancell was looking at BioNTech's study and accidentally gave a link to it. I guess the question is why?